Tagged with ERS

Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria.   From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…

Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…

Spain Andreu Mas-Colell, former minister of finance for Catalonia and president of the Barcelona Institute of Science and Technology (BIST), discusses the mission and activities of the institution as a driver of multidisciplinary research in the region. Mas-Colell also describes the condition of innovation and technology in Catalonia, highlights the region’s…

Korea Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the potential implications for the US-Korea FTA renegotiations.   The rate [of ageing] in Korea is actually even more serious than…

Malaysia Dr Hassan Yaakob of Healwell Pharmaceutical Co. Ltd., discusses the company’s rejuvenating and anti-ageing products, made from a polypeptide derived from sea cucumber. He also gives insights into the changing consumer preferences for his products, and the need to move marketing online in the digital world.   Our products sit between…

Turkey Prof. Dr. Sabahattin Aydın, Rector of Medipol University, chairman of the Executive Council of TUSAP Healthcare Platform, former executive board member of the World Health Organization (WHO), former deputy undersecretary (2003-2010) at the Ministry of Health of Turkey, and one of the most respected healthcare leaders in Turkey, provides insights…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…

Algeria Nadia Oka-Bousbia of bioMérieux Algeria discusses the affiliate’s important role within Algeria’s fight against infectious diseases and the training of health managers, difficulties surrounding import restrictions, and the company’s constantly-evolving strategy for the future.   These are exciting times for bioMérieux locally. We understand that earlier this year, your global…

Hong Kong Prof. Michael Yang, an accomplished scientist and start-up expert, introduces the goals of the fast-growing Biomedical Sciences Department of City University Hong Kong. He unveils the contribution of Hong Kong to the Greater Bay Area in the biomedical field, while analyzing the key elements to change so the region can…

Cyprus Christoforos Hadjikyprianou of the European University Cyprus, home to the island’s only state-of-the-art medical school, explains the institution’s unique value proposition and his vision for the future. Could you introduce yourself as well as European University Cyprus? “In the last decade-and-a-half we have made huge strides.” I am the University’s…

Hong Kong Louis Sze, CEO of Personal Surgical Modelling, an exciting Hong Kong start-up in the 3D printing medical technology field, shares the company’s achievements over the past few years, his insights on the regulatory and commercialization challenges related to such a groundbreaking new field of healthcare technology, and his main priorities…

UK Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse stakeholder groups, improving outcomes for UK patients.   We do see a will and an intent from stakeholders, from government…